Affymax Reports Phase 2 Clinical Dose Ranging Results of
Once-Per-Month Hematide for the Treatment of Anemia
PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - Affymax, Inc.
(Nasdaq:AFFY) today announced that additional Phase 2 clinical
trial results for Hematide(TM) were presented at the European Renal
Association-EDTA Congress being held in Barcelona, Spain by Iain C.
Macdougall, M.D., a Hematide
Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
...rt Takeda's efforts in the
clinical development of hematide
in chemotherapy induced anemia. We are
pleased wit...etics and preliminary
efficacy of various doses of hematide
in the correction of anemia. Initial
dosing in thi...al later stage clinical trials.
is a novel synthetic, pegylated peptidic compound ...
Affymax Announces Results From Phase 2 Clinical Trial of Hematide
for the Treatment of Anemia in Dialysis Patients
pharmacodynamics and pharmacokinetics of hematide
patients with stable baseline Hgb ...y. The endpoints were Hgb and
reticulocyte levels, hematide
dose adjustments and red blood cell
transfusions. ...n reticulocyte increases were
observed after every hematide
injection. The mean Hgb level, which
was 11.5 g/dL...
Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month
Hematide for the Treatment of Anemia in Patients with Early- and
End-Stage Chronic Kidney Disease
that in treatment naive, non-dialysis patients hematide
correct anemia when administered monthly at ...evels
following a switch to once monthly dosing of hematide
appropriate dose. The data were presented by...ing held in Rio
"These data show that hematide
results in appropriate management
of hemoglobin le...